PLBIO(SZ:000403)2016-04-28 16:00Financial Performance - The company's operating revenue for Q1 2016 was ¥164,181,419.42, representing a 48.09% increase compared to ¥110,863,871.87 in the same period last year[8]. - Net profit attributable to shareholders was ¥17,672,978.61, up 28.03% from ¥13,803,243.53 year-on-year[8]. - The net profit after deducting non-recurring gains and losses was ¥17,217,865.32, reflecting a 24.74% increase compared to the previous year[8]. - Basic earnings per share increased by 20.00% to ¥0.06 from ¥0.05 in the same period last year[8]. - Net profit increased by 41.22% year-on-year, driven by higher sales revenue.[18]. Cash Flow and Assets - The net cash flow from operating activities decreased by 3.27% to ¥35,207,745.62 from ¥36,398,980.43 in the previous year[8]. - Cash flow from operating activities increased by 41.58% year-on-year, mainly due to increased sales revenue from Guangdong Shuanglin Biopharmaceutical Co., Ltd.[19]. - Net cash flow from operating activities rose by 59.44% year-on-year, reflecting the growth in sales revenue.[19]. - Cash and cash equivalents increased by 37.44% compared to the beginning of the year, mainly due to increased sales revenue from Guangdong Shuanglin Biopharmaceutical Co., Ltd.[16]. - Cash and cash equivalents increased by 52.89% year-on-year, primarily due to higher cash from sales revenue.[22]. - Total assets at the end of the reporting period were ¥1,274,409,003.09, a 0.72% increase from ¥1,265,309,163.03 at the end of the previous year[8]. - Net assets attributable to shareholders increased by 3.25% to ¥516,718,253.24 from ¥500,456,490.63 at the end of the previous year[8]. Expenses and Costs - Operating costs rose by 64.23% year-on-year, mainly due to increased sales volume and corresponding production costs at Guangdong Shuanglin Biopharmaceutical Co., Ltd.[18]. - Sales expenses surged by 106.41% year-on-year, attributed to increased product sales from Guangdong Shuanglin Biopharmaceutical Co., Ltd.[18]. - Financial expenses increased by 61.06% year-on-year, mainly due to increased interest accruals at headquarters.[18]. - Business tax and surcharges increased by 39.16% year-on-year, primarily due to increased product sales from Guangdong Shuanglin Biopharmaceutical Co., Ltd.[16]. - Tax expenses increased by 70.58% year-on-year, corresponding to the rise in sales volume and related taxes.[18]. Corporate Actions and Compliance - The company has not planned any major asset restructuring since November 12, 2015, and will not engage in significant asset restructuring activities within the next six months[27]. - The company has successfully repaid all loans under the guarantee contract, and the guarantee responsibility has been released[28]. - The company reported no involvement in securities investments during the reporting period[30]. - There were no derivative investments made by the company during the reporting period[31]. - The company has not engaged in any non-compliant external guarantees during the reporting period[33]. - There were no non-operating fund occupations by controlling shareholders or their affiliates during the reporting period[34]. - The company is in discussions with creditors regarding new repayment plans[27]. - The company has received a notice of release from guarantee responsibilities related to a loan of 8 million yuan[28]. - The company has conducted communication and research activities regarding its production operations and related litigation during the reporting period[32]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,646[11]. Future Outlook - There is a warning regarding the potential for significant changes in net profit for the period from January to June 2016, but it is not applicable at this time[29].